Physician profile
Richard Marques
NPI 1811957749
$41,992.06
in general payments reported to CMS, 2019-2025
73 companies · $5,094 in 2025
The $5,094 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,866 · 2020: $5,127 · 2021: $8,739 · 2022: $5,044 · 2023: $5,262 · 2024: $5,861 · 2025: $5,094.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,216.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $6,435.11 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $4,422.13 | 2019-2025 | |
| Novo Nordisk INC | $3,505.21 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $3,486.93 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $2,964.01 | 2019-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $2,957.73 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,011.86 | 2019-2025 | Jardiance, Trijardy Xr, Synjardy |
| Pfizer INC. | $1,966.20 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $1,446.77 | 2021 | |
| Allergan, INC. | $1,405.34 | 2019-2020 | |
| Gilead Sciences, INC. | $1,162.10 | 2019-2025 | Descovy |
| Sanofi-Aventis U.S. LLC | $995.32 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $804.28 | 2019-2025 | |
| Amarin Pharma, INC. | $740.73 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $718.17 | 2019-2024 | Xarelto |
Show all 73 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Marques listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.